Innovative CRISPR-based Editing to Create Off-the-shelf Immune Cell Therapies

In this talk, first recorded at the 2022 IO360° Summit, Dr Rachel Haurwitz, CEO, Caribou Biosciences, addresses the big picture view of where the cell therapy field is going and how innovative CRISPR-based editing will help with the treatment of hematologic and solid tumors. Key topics include:

• Approach that requires highly specific and efficient multiplex genome editing
• What are some of the potential stumbling blocks?
• What are the tools for solving those challenges?
• Tackling solid tumors as the next frontier for cell therapies

Rachel Haurwitz, PhD, President & CEO, Caribou Biosciences

Learn more about the IO360° Summit at www.io360summit.com